🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Impact of Radiotherapy on Oligometastatic Cancer

Recruitingn/aAges 18 Years - anyAllInstitut Investigacio Sanitaria Pere Virgili
NCT05933876 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologic confirmation of primary tumor: breast, prostate, lung, colorectal. * 18 years old or older. * Up to five metastases located in the bone, lung, node, liver or brain. * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1. Exclusion Criteria: * Non-melanoma skin cancer. * Previous radiotherapy in the same anatomic location. * Presence of vascular collagen disease. * Pregnancy or lactation at the time of inclusion.
💊

What it tests

  • To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).
  • To propose a diagnostic test to determine the effectiveness of SABR.
  • To propose a diagnostic test for Oligometastatic Cancer (OC).
📍

Where

21 sites
Complejo Hospitalario Universitario Albacete
Albacete, Spain
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Institut Català d'Oncologia
Barcelona, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Hospital Universitari Arnau de Vilanova
Lleida, Spain
Hospital de La Luz
Madrid, Spain
Hospital Ruber Internacional
Madrid, Spain

…and 13 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy